Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A03AE
|
| gptkbp:brand |
gptkb:Viberzi
|
| gptkbp:CASNumber |
845442-38-2
|
| gptkbp:contraindication |
alcoholism
pancreatitis severe liver impairment biliary duct obstruction |
| gptkbp:developer |
gptkb:Furiex_Pharmaceuticals
gptkb:Actavis |
| gptkbp:hasMolecularFormula |
C32H35N5O5S
|
| https://www.w3.org/2000/01/rdf-schema#label |
eluxadoline
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
mu-opioid receptor agonist
delta-opioid receptor antagonist kappa-opioid receptor agonist |
| gptkbp:molecularWeight |
569.72 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
abdominal pain constipation pancreatitis |
| gptkbp:usedFor |
irritable bowel syndrome with diarrhea
|
| gptkbp:bfsParent |
gptkb:Furiex_Pharmaceuticals
gptkb:IBS-D |
| gptkbp:bfsLayer |
7
|